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Introduction
Over the last three decades, a series of clinical trials have led to
the use of adjuvant pelvic radiotherapy and chemotherapy in
high-risk (T3–4 or N1) rectal cancer. The recently reported
Dutch trial,1 where total mesorectal excision (TME) was the
standard surgery, was seminal in defining the role of adjuvant
therapy in rectal cancer with optimal surgery. Preliminary data
showed that, with preoperative radiotherapy alone, the 2-year
local recurrence (LR) rate improved from 8.2% to 2.4% (p <
0.001).1 The absolute improvement in 2-year LR of 5.8% would
mean approximately 17 patients would require treatment to
prevent one recurrence. In addition, it is still uncertain if there
is any improvement in survival. There is a suggestion that the
oncological benefit of adjuvant therapy might be greater with
non-TME surgery.2
There is a need to improve patient selection in order to
identify the group most at risk for recurrent disease. The
toxicity of adjuvant therapy should be factored into this
consideration. The optimal sequencing of adjuvant therapy
before or after surgery, the use of short- or long-course
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radiotherapy, and the utility of concurrent chemotherapy is
currently being examined in randomized controlled trials
(RCTs). The aim of this report was to review the morbidity and
mortality in all RCTs of adjuvant therapy for rectal cancer.
Method
A MEDLINE literature review was performed for English
language publications on adjuvant therapy for rectal cancer,
from 1966 to 2002 (37 years), with the keywords rectal cancer,
adjuvant therapy and randomized, controlled trial. A total of
2,191 publications on adjuvant therapy for rectal cancer were
retrieved. Review articles, personal views, abstracts, non-
randomized trials, pilot studies, and studies involving ad-
vanced unresectable or metastatic rectal cancers were excluded.
Modalities of adjuvant therapy evaluated included preopera-
tive radiotherapy, preoperative combined chemotherapy
and radiotherapy, postoperative radiotherapy and postopera-
tive combined chemotherapy and radiotherapy. Other
modalities of adjuvant therapy such as immunotherapy,
intraoperative radiotherapy and unconventional drug therapy
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were excluded. A total of 42 RCTs on resectable rectal cancer
were reviewed.
The morbidities specifically sought were gastrointesti-
nal complications (stomatitis, diarrhoea and intestinal
obstruction), surgical complications (abdominal wound
infection, perineal wound infection, anastomotic leak and
pelvic sepsis), radiation cystitis, haematological complica-
tions and dermatological complications. In areas where there
was a lack of data from RCTs, representative results from
non-randomized studies are discussed.
Postoperative adjuvant combined chemother-
apy and radiotherapy
Postoperative chemoradiotherapy with 5-fluorouracil (5FU)
is the only adjuvant therapy shown by RCTs to reduce LR and
improve survival in high-risk rectal cancer.3–6 Protracted
venous infusion (PVI) of 5FU is more effective for survival than
bolus delivery.7 The recently reported National Surgical
Adjuvant Breast and Bowel Project (NSABP) R02 study
confirmed the advantage of adjuvant postoperative chemo-
radiotherapy despite optimal surgery.8 Adjuvant therapy
significantly reduced cumulative locoregional relapse from
13% to 8% at 5 years. No survival difference was detected.
However, bolus 5FU therapy rather than PVI 5FU was used
during the concurrent radiotherapy phase. The toxicities of
postoperative chemoradiotherapy have been reported in 11
RCTs.3–13
Mortality
The reported mortality rate in eight RCTs ranged from
0.3% to 4% (Table 1).3–5,7–11 In three other RCTs, the mortality
was not stated.6,12,13 The main causes of death were sepsis
(40%), intestinal obstruction or perforation (50%) and perito-
nitis (10%). All three deaths in the Copenhagen trial (18%) were
related to severe radiation enteritis, with subsequent intestinal
obstruction, perforation and sepsis.14 The high mortality rate
in this study was probably because of both the unconventional
use of concurrent methotrexate, which acts as a radiation
sensitizer, and the now obsolete two-field irradiation technique.
The results are not presented in Table 1 as the trial was pre-
maturely terminated after 34 patients had been treated for fre-
quent and serious complications.14
Acute adverse effects
Acute gastrointestinal and haematological toxicities may be
considerable and are sometimes severe or life-threatening.
Major acute gastrointestinal toxicity includes severe diarrhoea
(11–41%), nausea (4–38%), vomiting (2–11%) and stomatitis
(5–27%). In the Gastrointestinal Tumor Study Group (GITSG)
study, severe and life-threatening acute toxicities (Eastern
Cooperative Oncology Group, ECOG, grades 3–415) occurred
in 61% of patients after chemoradiotherapy, compared with
18% and 31% after radiotherapy or chemotherapy alone,
respectively.3 Myelosuppression and severe diarrhoea are
increased with combined therapy compared to either che-
motherapy or radiotherapy alone.
Haematological
Haematological toxicity has been reported in all major studies
of combined therapy. Leucopenia (total white cell count, < 2 ×
103/mL) occurred in 28% of the combined group compared
with 2% and 13% after radiotherapy or chemotherapy alone in
the GITSG study.3 However, most of these leucopenias were
without serious clinical sequelae. Krook et al reported similar
data in the first North Central Cancer Treatment Group
(NCCTG) study.4 Both studies used a now unconventional
combination of 5FU and methyl-chloroethylcyclohexylnitro-
sourea (MeCCNU), which almost certainly increased overall
toxicity.
Nausea
Nausea has been reported in up to 38% of patients who receive
postoperative chemoradiotherapy. The rates vary from study
to study depending on whether all grades of nausea or only
severe or life-threatening reactions are reported. Nausea
occurred in 38% of the chemoradiotherapy group receiving
5FU alone compared with 6% in the radiotherapy alone arm in
the Krook et al study.4 When severe nausea only was consid-
ered, 2% and 0% were affected, respectively. The addition of
semustine increased the risk of nausea to 73%, of which 10%
was severe. O’Connell et al reported no difference in the inci-
dence of severe or life-threatening nausea between the che-
motherapy alone arm with 5FU and the chemoradiother-
apy arms with PVI or bolus 5FU (1% in each arm).7 The likeli-
hood of developing any nausea, particularly severe nausea,
is dependent on the chemotherapeutic agent used, and is
worse with combination chemotherapy.4,7
Diarrhoea
In the Krook et al study,4 postoperative chemoradiotherapy
produced a significantly increased rate of severe or life-threat-
ening diarrhoea (National Cancer Institute Common Toxicity
Criteria ≥ grade 316,17) in patients receiving bolus 5FU (22%)
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compared to patients receiving postoperative radiotherapy
alone (4%). The increased rates of diarrhoea during adjuvant
therapy were manifested across all toxicity levels for patients
receiving postoperative chemoradiotherapy. Comparing post-
operative radiotherapy alone and postoperative chemoradio-
therapy, the incidences of diarrhoea were as follows: grade
0, 59% vs 21%; grade 1, 20% vs 34%; grade 2, 17% vs 23%; grade
3, 4% vs 20%; and grade 4, 0% vs 2%.16 In addition, increased
rates of any diarrhoea and of severe or life-threatening diar-
rhoea were observed in patients who had undergone anterior
resection compared to those who had undergone abdomi-
noperineal resection (APR). In the GITSG trial,3 grade 3–4
diarrhoea occurred in 2% of patients receiving postoperative
radiotherapy alone, in 6% of patients receiving chemotherapy
alone, and in 20% of patients receiving postoperative che-
moradiotherapy.
The second NCCTG study demonstrated the oncological
superiority of PVI 5FU over bolus 5FU when given concur-
rently with radiotherapy.7 However, the rate of severe diar-
rhoea was significantly higher among patients who received
PVI 5FU compared to bolus 5FU.17 The risk did not appear to
persist after completion of radiotherapy, indicating that at the
doses used, no recall toxicity was evident. Patients who had
undergone anterior resection had a higher rate of severe diar-
rhoea than patients who had undergone APR (31% vs 12%),
consistent with the Krook et al study.4 Otherwise, there was no
significant increase in severe toxicities with PVI 5FU. Severe
leucopenia is significantly more common in patients who
Table 1. Randomized controlled trials of adjuvant postoperative chemotherapy and radiotherapy for rectal cancer
Trial GITSG NCCTG GITSG NCCTG Oslo6 INT 01149 NSABP NSABP Genoa10 German Univer-
71753 Krook 71805 O’Connell R028 R0312 (CAO/ sity of
et al4 et al7 ARO/ Uslan13
AIO-94)11
Treatment 40 Gy/ 50.4 Gy/ 40 Gy/ 45 Gy/ 46 Gy/ 50.4 Gy/ 50.4 Gy/ 50.4 Gy/ 50 Gy/ 50.4 Gy/ 45 Gy/
schedule 20 for 28 for 20  for 25 for 23 for 28 for 28 for 28 for 25 for 28 for 25 for
4 W + 5.5 W +  4 W + 5 W + 4 W + 5.5 W + 5.5 W + 5.5 W + 5 W + 5 W + 5 W +
5FU/ 5FU/ 5FU/ bolus or bolus 5FU 5FU w/wo 5FU/FA 5FU/FA 5FU/ 5FU 5FU/FA
MeCCNU semustine semustine PVI 5FU FA or FA/ levamisole
or esca-  w/wo levamisole
lating 5FU semustine or levamisole
N 46 104 210 660 72 1,696 694 137 110 310 308
Follow-up (mo) 94 84 70 46 96 48 93 12 28 NS 37
Complications (%)
   Mortality 4 2 4 0.3 0 1.5 1 0 1.5 1.6 0
   Stomatitis NS 27 NS 7 NS 5–12 21 NS 41 3 7
   Severe diarrhoea 19 35 NS 24 11 19–35 31 12 14 13 7
   Nausea NS 38 NS 4 16 NS NS NS 33 3 NS
   Vomiting 6 11 NS 3 4 2–5 6 NS NS 3 4
   SBO 5 5 3 5 4 6 NS NS NS NS NS
   Enteritis 4 NS NS NS NS NS NS NS NS NS NS
   Rectal radiation 5 NS NS NS NS NS NS NS NS NS NS
      stricture
   Thrombocytopenia 17 9 1 15 0 1 0 NS 3 NS 0
   Leucopenia 28 33 5 30 25 37–49 3 NS 20 3 3
   Dermatitis 8 28 NS 3 33 NS 3 NS 9 3 1
   Second primary NS 5.8 0.4 NS NS NS 5.9 1.6 NS NS NS
      cancer
Completion rate (%) 65 83 83 87 89 77–82 92.5 NS 90 NS 88
GITSG = Gastrointestinal Tumor Study Group; NCCTG = North Central Cancer Treatment Group; INT = Intergroup; NSABP = National
Surgical Adjuvant Breast and Bowel Project; W = weeks; 5FU = 5-fluorouracil; MeCCNU = methyl-chloroethylcyclohexylnitrosourea;
w/wo = with or without; FA = folinic acid; NS = not stated; SBO = small bowel obstruction.
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receive bolus 5FU. The use of folinic acid (FA) or levamisole
in combination with 5FU is also associated with increased
gastrointestinal toxicity without improved efficacy.9
Given the severity of gastrointestinal toxicity, a range of
strategies has been investigated in an attempt to prevent or
reduce diarrhoea during pelvic radiotherapy. Besides dietary
modifications,18 the combination of diphenoxylate and atro-
pine (Lomotil®), and loperamide (Imodium®) has been used.
In severe diarrhoea, however, excessive use of anti-diarrhoeal
medication may precipitate an ileus. Other agents such as
olsalazine,19 cholestyramine20 and sucralfate21 are either inef-
fective or the related toxicity is unacceptable. More recently,
octreotide has been shown in an RCT to be more effective than
the combination of diphenoxylate and atropine.22 However,
octreotide is expensive and requires subcutaneous admin-
istration. Longer-acting octreotide may prove to be a more
acceptable alternative.
Tolerability
Frequent and severe toxicities related to postoperative
chemoradiotherapy lead to completion rates of only 65%
(GITSG study3) and 83% (Krook et al4). Patients may some-
times refuse to continue with treatment. In contrast to the
GITSG trial,3 where treatment was delivered over 18 months,
it is now usual to treat patients for only 6 months. As a result,
the completion rate with the modern approach would be
expected to be much higher; the latest studies have consis-
tently demonstrated this, with completion rates at around
85% to 95%.7,8,10,13 Early radiotherapy treatment commencing
with the first cycle of chemotherapy demonstrated not only
improved disease-free survival but also improved patient
compliance.13 Radiotherapy of 40 Gy or more was given to 96%
of patients who had early chemoradiotherapy compared with
90% who had late chemoradiotherapy.
In the Copenhagen trial, acute toxic symptoms were not-
ed in many patients, and included nausea (100%), vomiting
(100%), diarrhoea (100%), stomatitis (40%), and severe radia-
tion cystitis (11%).14 Possible reasons for the very high level of
toxicity were the use of a two-field technique incorporating
large irradiated volumes (upper level of field at L2 vertebral
level) and the combined use of methotrexate, a known radia-
tion sensitizer. These techniques are no longer used.
Late adverse effects
Long-term radiation effects include radiation enteritis (up to
4%), small bowel obstruction (SBO) (up to 5%), and radiation
stricture (up to 5%).
Radiation enteritis
In the GITSG study,3 all the five patients (4%) with radiation
enteritis required laparotomy and two died. In the Krook et al
study,4 SBO requiring surgery occurred in 7% of patients
receiving chemoradiotherapy. The higher incidence of SBO
after postoperative radiotherapy compared with preoperative
radiotherapy may be secondary to postoperative adhesions
and the prolapse of small bowel loops into the irradiated
pelvis. The incidence of SBO increases by 30% to 40% if the
radiation fields extend higher into the abdomen.23–25 The
extent of this problem seems to be related to the volume of the
irradiated small bowel. This underscores the importance of
precise radiation techniques that exclude the small bowel
from the irradiated fields. Methods to reduce this exposure
include small bowel contrast (gastrografin) to highlight the
small bowel position, treatment in a prone position with a full
bladder or on a belly board to force the small bowel in a
cephalad direction, multiple radiation fields to reduce the
volume of the irradiated small bowel and dosimetric hot spots,
and appropriate shielding.26 However, in the postoperative
setting, irradiation of adherent small bowel loops can still
occur. Surgical manoeuvres and devices such as an omental
sling, resorbable polyglycolic-acid mesh, reperitonealizing the
pelvic floor or suturing the posterior wall of the bladder to the
pelvic sidewalls may be used.27–31 However, despite these sur-
gical manoeuvres, prolapse of the small bowel into the pelvis
and radiation of loops of small bowel at the pelvic brim can
still occur.32,33
More recent publications have reported a lower incidence
of SBO requiring surgery. This may be related to better surgi-
cal or radiotherapy techniques. The O’Connell et al study,7
which used a bolus 5FU arm similar to the original Krook et al
study,4 reported this complication in only 3% of patients. The
PVI 5FU arm was similar, with 4% of patients affected. The
Intergroup 0114 trial reported this complication in 6% of
patients but included those who required surgery as well as
patients receiving conservative inpatient hospital care.9
Bowel function
While there are no long-term prospective randomized control-
led data on bowel function following postoperative chemo-
radiotherapy, retrospective studies suggest a range of detri-
mental effects.34,35 Patients receiving postoperative chemo-
radiotherapy had more bowel movements per day, clustering
of bowel movements and nocturnal bowel actions. More of
these patients wore a pad and were unable to defer defaecation
for more than 15 minutes. They also had a higher incidence
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of liquid than firm stools, greater use of anti-diarrhoeal medi-
cations, more perineal skin irritation, more difficulty in dif-
ferentiating stool from gas, and more stool fragmentation. It
is probable that the clinical consequences of postoperative
chemoradiotherapy are related to decreased rectal capacity
and compliance. However, changes in rectal motor and sen-
sory function and changes in surrounding soft tissues may
also contribute. Anal sphincter function might be affected if
it is within the radiation fields, as is required with a low rectal
cancer.
Sexual function
Sexual function after adjuvant chemoradiotherapy was not
evaluated formally in any of the RCTs. There are retrospec-
tive reports of dyspareunia in women and impotence (5%) in
men.35 The effect of adjuvant chemoradiotherapy on fertility
and menstrual status is not clear, although moderate to high
doses (≥ 20 Gy) of radiotherapy are known to sterilize most
fertile women.36 Chemotherapy alone may cause early meno-
pause, especially in older women receiving adjuvant treatment
for breast cancer;37 however, there are no available data on
5FU.
Second malignancy
One well-recognized late effect of radiotherapy is an increased
risk of a second primary malignancy within the radiation
field. A second primary cancer developed in 5.8% of patients
in the Krook et al study,4 affecting the brain, breast, colon,
endometrium, kidney, larynx, lip, lung and pancreas. The
NSABP R02 trial reported second primary cancers in 5.9% of
patients, with an increased rate of colon and prostate cancer in
the 5FU, semustine and vincristine (MOF) arm (8.7% with
MOF vs 7.7% without MOF).8 Other cancers such as lung,
bladder, breast and malignant melanoma were evenly distrib-
uted across the four chemotherapy regimens. There was no
reported leukaemia or blood dyscrasia. These observations
have not been reported in any other major study. The GITSG
study reported an increase in acute non-lymphatic leukaemia
after exposure to MeCCNU, but this known leukaemogenic
agent is no longer used.3
Postoperative adjuvant radiotherapy alone
Eleven RCTs on postoperative radiotherapy alone for stage II–
III resectable rectal cancer were reviewed.4,10,25,38–45 Most stud-
ies used modern radiotherapy techniques with at least three
fields and radiation doses of 40 to 60 Gy with conventional
fractionation (1.8–2.3 Gy). Postoperative radiotherapy alone
is now rarely used except in the management of a locally
excised small rectal cancer or if the patient refuses chemo-
therapy.
Mortality
Mortality after postoperative radiotherapy varies from 0% to
5% (Table 2). The Uppsala study reported the highest mortal-
ity,38 whereas other studies reported rates of 1% to 2%.10,25,39 A
possible reason for the discrepancy is the older patient popu-
lation in the Uppsala study (median, 70 years). Total radiation
doses were also higher (60 Gy). Five of the 10 deaths in the
Uppsala study were possibly caused by radiotherapy-related
complications such as anastomotic dehiscence (n = 1), sepsis
(n = 1), and ileus (n = 3). Deaths often followed surgical
intervention for radiotherapy-related complications such as
SBO from complex adhesions or radiation enteritis.
Acute adverse effects
Acute toxicities after postoperative radiotherapy for rectal
cancers are shown in Table 2. Gastrointestinal, urological and
dermatological complications were noted. Diarrhoea (8–48%),
nausea (4–17%), skin reactions (8–28%), radiation cystitis
(6–12%) and fatigue (14%) were common. Because of these
toxicities, a proportion (12–50%) of patients did not complete
the planned radiation dose. The completion rate of postopera-
tive irradiation in the Uppsala study was only 49%,38 whereas
it was 85% in the Danish study25 and 73% in the Rotterdam
trial.39 Possible reasons were an older patient population and
a higher total radiation dose in the Uppsala trial. However,
criteria for ceasing radiotherapy were not clearly defined.
Although most toxicities are mild, more serious complica-
tions requiring hospitalization or surgical intervention do oc-
cur. In the Uppsala trial, five (7%) patients required hospitali-
zation for parenteral nutrition because of severe diarrhoea.38
Severe (ECOG grade 3–415) gastrointestinal toxicities were
observed in 4% of patients in the GITSG trial.3,40
Late adverse effects
SBO occurs in 5% to 11% of patients after postoperative ra-
diotherapy.4,38,41,42 Ileus and intestinal perforation are more
common if the radiation dose delivered is more than 45 Gy.25
In the Danish study, 10% of patients required further opera-
tions for SBO or intestinal perforation.25 All five patients with
intestinal perforation had received a radiation dose of more
than 45 Gy. The addition of chemotherapy did not appear to
increase the incidence of SBO.
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Table 2. Randomized controlled trials of adjuvant postoperative radiotherapy for rectal cancer
Trial No. of Total dose (Gy)/ N Mortality (%) Morbidity Completion
fields no. of fractions rate (%)
Denmark25 3 50/25 244 2 Ileus 10% 85
Perforation 10%
GITSG 717540 2 43.5/24 50 0 Radiation enteritis 4% NS
NSABP R0144 2 47/26 184 0 Not increased but details NS 84
NCCTG Krook 3–4 50.4/28 100 1 Diarrhoea 47% 98
   et al4 Severe diarrhoea 5%
SBO 4%
Radiation enteritis 1%
ANZ-BCT45 4 45/25 36 NS Diarrhoea 38% 95
Nausea 14%




Uppsala38 3 60/30 235 5 SBO 11% 49
Radiation cystitis 6%
Skin reaction 12%






EORTC42 4 46/23 84 0 Chronic diarrhoea 20% 72
Chronic cystitis 12%








EORTC43 Limited-XRT 4 50/25 229 1 Severe late intestinal complications:
  26/167 at risk 87
Extended-XRT 50/25 plus 222 1 Severe late intestinal complications:
4 plus 2  25/19   18/158 at risk 72
GITSG = Gastrointestinal Tumor Study Group; NSABP= National Surgical Adjuvant Breast and Bowel Project; NCCTG = North Central Cancer
Treatment Group; ANZ-BCT = Australia and New Zealand Bowel Cancer Trial; UKMRC = United Kingdom Medical Research Council;
EORTC = European Organisation for Research and Treatment of Cancer; NS = not stated; SBO = small bowel obstruction; XRT = irradiation.
The European Organisation for Research and Treatment
of Cancer (EORTC) trial of postoperative pelvic radiotherapy
with or without elective irradiation of para-aortic nodes and
liver reported an increased incidence of severe late intestinal
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complications in patients who were randomized to the ex-
tended fields.43 Among the 167 patients at risk in the pelvic
radiotherapy arm, 26 developed severe late intestinal
complications, 18 of whom required surgery. Among the 158
patients at risk in the extended field arm, 18 developed severe
late intestinal complications, of whom 11 required surgery.
No survival difference was seen, demonstrating the futility of
treating higher-echelon lymph nodes.
Of all the RCTs investigating the role of postoperative
radiotherapy in rectal cancer, only the Danish study has pro-
duced follow-up data on long-term bowel function.46 Com-
pared to patients who did not receive postoperative radio-
therapy, those who received postoperative radiotherapy had
more bowel movements per day, greater faecal urgency, more
faecal incontinence, and wore a pad more often. They also
had stool of liquid consistency, used anti-diarrhoeal medica-
tions more often, had perineal skin irritation, and were less
able to differentiate stool from gas. This agrees with the results
of a detailed retrospective report of long-term bowel function
in patients receiving postoperative chemoradiotherapy.35 The
mechanisms underlying the dysfunction would presumably
be no different. Whether chemotherapy further worsens anorec-
tal function is unknown.
Preoperative adjuvant radiotherapy alone
Preoperative radiotherapy is either administered as short-
course radiotherapy or over a longer course with concurrent
chemotherapy. Long-course radiotherapy was arrived at em-
pirically and is based on experiments demonstrating that the
minimum dose required to eradicate micrometastases ranges
from 45 to 50 Gy in 1.8 to 2 Gy fractions for 5 weeks.47,48 The
short-course variation that is used widely in Europe was devel-
oped for practical and economical reasons, allowing the radio-
therapy to be delivered in 1 week with surgery accomplished
the following week. The chosen regimen of 25 Gy in five
fractions is considered biologically equivalent to long-course
radiotherapy for late effects.49,50 The relative merits of long-
course and short-course radiotherapy have been reviewed else-
where.51
A total of 21 RCTs of preoperative radiotherapy for resect-
able rectal cancer were evaluated (Tables 3 and 4).1,2,41,52–68
In these studies, dosing schedules included 20 to 25 Gy in
five fractions and 40 to 54 Gy in 20 to 30 fractions. Notably, in
this indirect comparison, there was no significant difference
in complication rates between short- and long-course radio-
therapy, apart from a higher incidence of perineal wound
infection after abdominoperineal excision of the rectum in
patients who received preoperative high-dose, short-course
radiotherapy.1,2,57,58
Mortality
The mortality after long-course radiotherapy was 0% to 6.6%,
and after short-course radiotherapy was 0% to 9% (Tables 3
and 4). Four studies contributed to the higher end of the range
(7.6–9%) with short-course radiotherapy.56–58,60 All four trials
used a two-field irradiation technique encompassing at least
the upper level of the second lumbar vertebra, with the conse-
quence that a large volume was irradiated. The excess mortal-
ity was mostly demonstrated in elderly patients (> 75 years),
in whom the causes of death were predominantly cardiovascu-
lar and infectious complications, with thromboembolism
(13%) accounting for most deaths.60 The causal relationship
between irradiation and cardiovascular disease is not apparent,
but the risk appears to be increased when large volumes are
irradiated.
It is notable that in the Stockholm (I/II) trial,58 mortality
was reduced from 8% to 2% when a four-field rather than a two-
field irradiation technique was used. In more recent trials,
three- and four-field irradiation techniques were used to limit
the superior border of radiotherapy to L5–S1. In the Uppsala
trial,61 where the same radiation dose and schedule were used
with a three-field technique, no increase in postoperative mor-
tality was found. Similarly, in the Swedish Rectal Cancer Trial
(SRCT) involving 583 patients,2 the use of a three- or four-
field technique did not affect postoperative mortality. Mortal-
ity in the surgery-alone vs three- or four-field technique arms
was exactly the same (2.6% in each arm). In hospitals that, for
unexplained reasons, used a two-field technique, the post-
operative mortality was increased. The Dutch trial,1 which
mandated a three- or four-field technique, demonstrated no
increase in postoperative mortality. Surprisingly, the United
Kingdom Medical Research Council (UKMRC) trials41,55 and
EORTC trial,64 which used a two-field technique, reported no
increase in postoperative mortality. This raises the possibility
that increased mortality is an effect of large fraction size.
Acute adverse effects
Short-term (acute) complications of preoperative radio-
therapy include lethargy, nausea, diarrhoea (7–30%) and skin
erythema or desquamation (< 5%). These acute reactions de-
velop to some degree in most patients during treatment but
are self-limiting and usually resolve within weeks of com-
pletion.2,41,55,56
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Table 3. Randomized controlled trials of adjuvant short-course preoperative radiotherapy for rectal cancer
Trial No. of  fields Total dose (Gy)/no. of fractions N Mortality (%) Morbidity
Memorial52 2 20/8 376 5.3 NS
VASOG53 2 20/10 347 NS NS
Toronto54 2 5/1 60 0 0
UKMRC 1b55 2 20/10 272 3.3 Wound infection 10%
Perineal wound infection 23%
Pelvic sepsis 8%
Anastomotic leak 8%
UKMRC 1a56 2 5/1 277 8 Wound infection 11%
Perineal wound infection 16%




Stockholm I58 2 25/5 424 8 Wound infection 14%
Anastomotic leak 13%




Uppsala38 3 25.5/5 236 3 SBO 5%
Radiation cystitis 2%
Skin reaction 2%
NW England59 3 20/4 143 NS NS
St. Marks60 2 15/3 228 9 Perineal wound breakdown 26%
Anastomotic leak 15%
Thromboembolism 13%
SRCT2 3–4 25/5 583 4 Wound infection 4.5%
Perineal wound infection 20%
Anastomotic dehiscence 4.7%
Ileus 4.8%
Uppsala61 3–4 25/5 632 NS NS
Dutch1 3–4 25/5 924 4 Diarrhoea 2%
Increased blood loss*
Ileus 5%
Perineal wound infection 29%
Cardiac 5%
VASOG = Veterans Administration Surgical Oncology Group; UKMRC = United Kingdom Medical Research Council; SRCT = Swedish Rectal
Cancer Trial; NS = not stated; SBO = small bowel obstruction. *Blood loss: 1,000 mL with radiotherapy vs 900 mL without radiotherapy (no
percentage given).
Neuropathy
The frequency of acute lumbosacral plexopathy during and
after short-course preoperative radiotherapy for rectal cancer
has been reported to be as high as 6%.69 In this series, the pain
was usually localized in the lower lumbar region and of short
duration, but pain was persistent in approximately 1% of
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patients. Acute neurogenic pain was more common in women
than men and in patients with underlying diabetes mellitus or
neurogenic disorders. These symptoms are thought to be the
result of acute radiation damage to the peripheral nerves and
theoretically can be eliminated by avoiding irradiation above
the pelvis. However, in the Dutch trial,1 where the upper level
of the radiation field was situated at the L5–S1 junction, such
symptoms were reported in 53 patients, 18 of whom required
interruption of treatment.
Wound complications
In all trials using moderate- or high-dose preoperative ra-
diotherapy, a higher incidence of perineal wound infections
has been reported among patients following abdomino-
perineal excision of the rectum. A two-fold increase in this
complication was seen with both short- and long-course
radiotherapy. However, when the perineum is not included in
the target volume, there is no increase in perineal wound
complications.11
Anastomotic complications
There is no reported increase in the dehiscence of colorectal
anastomosis (7–15%) or ileus (5%) following preoperative
radiotherapy. The reported incidence of clinically sympto-
matic anastomotic leaks after an anterior resection is 3% to
11%. This lack of anastomotic complications may be related
Table 4. Randomized controlled trials of adjuvant long-course preoperative radiotherapy for rectal cancer
Trial No. of  fields Total dose (Gy)/no. of fractions N Mortality (%) Morbidity
Yale62 2 46/23 15 6.6 NS
VASOG63 2 31.5/18 180 0.6 Thromboembolism 7.7%
Septic complication 12.5%
Haematological complication 7.1%
EORTC64 2 34.5/15 166 4.6 Wound infection 15%
Perineal wound infection 48%
Perineal sinus 21%
Cystitis 20%
Sao Paolo65 2 40/25 34 2.9 Radiation cystitis 8.8%
Skin reaction 5.8%
Norway66 2 31.5/18 159 4.2 Wound infection 5.5%









UKMRC 241 2 40/20 139 3.5 Wound infection 6%
Perineal wound infection 7%
Pelvic sepsis 17%
Anastomotic leak 7%
Lyon R90-0168 3 39/13 201 3.5 Anastomotic complication 17.5%
(fistula, intra-abdominal
abscess, peritonitis)
VASOG = Veterans Administration Surgical Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer;
UKMRC = United Kingdom Medical Research Council; NS = not stated; SBO = small bowel obstruction.
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to resection of the irradiated rectum and construction of the
colorectal anastomosis in a healthy undamaged portion of the
rectum. A diverting stoma is generally recommended because
of the extensive pelvic dissection often necessary and distal
colorectal anastomosis.
Late adverse effects
In the Stockholm I trial,58 the use of high-dose short-course
preoperative radiotherapy with larger irradiated volumes led
to an increase in thromboembolic events (7.5%), femoral neck
and pelvic fractures (5.3%), delayed perineal wound healing
(20%), intestinal obstruction (13.3%), and postoperative fis-
tula (4.8%). Pelvic fractures occurred only among patients
treated in Stockholm, where radiation shielding was not part
of routine practice. However, when a four-field technique with
the same radiation dose was used in the Stockholm II trial,58
there was no increase in these complications, suggesting that
precise target volume definition may help to avoid unneces-
sary exposure of normal tissues. The Dutch trial reported no
increase in femoral neck and pelvic fractures in patients re-
ceiving preoperative radiotherapy.1 However, it reported a
statistically significant increase in cardiac events (5% vs 3%),
which again emphasizes the impact of fraction size on the
cardiovascular system.
Small bowel obstruction
The incidence of SBO is approximately 5% to 13% in patients
receiving preoperative radiotherapy.38,58,66 The risk is related
to total dose, dose per fraction, number of radiation fields and
volume of small bowel included in the radiation field.23 This
complication increases as the total radiation dose increases,
as shown by the Norwegian study66 and the postoperative ra-
diotherapy trials (40–60 Gy).25 Larger radiation fields will also
mean a greater volume of small bowel being irradiated, as
reported in the Stockholm I trial,58 where higher field place-
ment (upper level at L2) and a two-field technique led to much
larger volumes of small bowel being irradiated. This was not
shown in the SRCT and Dutch trials,1 where small bowel
exposure was minimized.
Sphincter function
The impact of preoperative radiotherapy on sphincter func-
tion remains uncertain. The SRCT trial showed that short-
course preoperative radiotherapy had a negative impact on
anal function.70 There was an increase in bowel frequency,
urgency and faecal incontinence. However, the anus was in-
cluded in the radiation fields, which could induce direct dam-
age to the anal sphincters and the pudendal nerves. Damage to
the sphincters can result in postradiation fibrosis, especially
if the biologically equivalent doses calculated for high-dose
short-course radiotherapy for the sphincters are inaccurate.
To date, the investigators from the Dutch trial have not re-
ported on late complications.1 In the Lyon study,68 long-
course preoperative radiotherapy using conventional frac-
tionation does not appear to incur the same level of anorectal
dysfunction. We await more detailed functional data from the
German11 and Polish studies,71 which are now completed.
Data on sexual dysfunction are limited. Results from the
Dutch trial72 suggest that radiotherapy had little or no adverse
effect on sexual function, above and beyond that induced by
surgery.
Preoperative adjuvant combined chemother-
apy and radiotherapy
The use of preoperative adjuvant combined chemotherapy
and long-course radiotherapy has been adopted as standard
treatment in many centres outside Europe, despite a lack of
RCTs.
This approach commences with long-course convention-
ally fractionated radiotherapy concurrently with PVI or bolus
5FU followed, after a 6- to 8-week interval, by surgical resec-
tion and further postoperative bolus 5FU chemotherapy. The
radiotherapy technique is no different to that given in the
postoperative setting, using computed tomography simula-
tion where available and small bowel exclusion protocols (e.g.
multiple radiation fields). The radiation dose may vary but will
always consist of a minimum of 45 Gy delivered to the pelvis,
which may be followed by a boost of 5.4 Gy to the gross tumour
volume in 1.8 Gy fractions delivered at five fractions/week over
5.5 weeks.
The first randomized trial of preoperative combined chemo-
therapy and radiotherapy was conducted by the EORTC and
published in 1984.73 A number of RCTs have recently been
completed or are about to complete accrual (Table 5).11,12 The
most important of these is a large German study in which
patients were randomized to either pre- or postoperative com-
bined-modality therapy.11 This study has just been completed.
Two other similar studies, the NSABP R0312 and the INT1047,
were both terminated prematurely due to poor patient accrual.
Mortality
The mortality after preoperative chemoradiotherapy in three
published RCTs ranged from 1.6% to 8.9%. The causes of death
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were mainly cardiovascular and pulmonary related.
In the EORTC trial,73 247 patients were randomly assigned
to receive preoperative radiotherapy with or without 5FU.
The mortality rate was higher among patients receiving pre-
operative combined therapy (8.9%) than preoperative radio-
therapy alone (5%).
A preliminary report from the NSABP R03 study,12 where
patients were randomly assigned to receive either pre- or
postoperative chemoradiotherapy using modern techniques,
recorded two deaths in the preoperative group and one in the
postoperative group. The causes of death were myocardial
infarction (n = 2) and pulmonary embolism (n = 1). A similar
progress report from the German study detailed the deaths of
three patients in the preoperative chemoradiotherapy arm
while receiving therapy.11 This included two deaths from
myocardial infarction occurring during or shortly after the
first 5FU chemotherapy cycle and one case of pulmonary
embolism. Two patients died after surgery, from cardiac fail-
ure and sepsis, respectively. In the postoperative chemoradio-
therapy arm, three patients died after surgery and one died
from pulmonary embolism while receiving postoperative
therapy. Thus, preliminary data from contemporary studies
have not shown any increase in mortality with preoperative
combined-modality therapy.
The higher mortality rate in the EORTC study was thought
to be consistent with the more elderly patient population,
which included a large number of patients with coexisting
cardiovascular and pulmonary diseases. Another possible
explanation was the antiquated two-field technique, a risk
factor, especially in elderly patients with co-existent cardio-
vascular diseases.
Acute adverse effects
Acute and severe adverse effects were encountered in six pa-
tients treated with chemoradiotherapy in the EORTC trial.73
Other side effects were diarrhoea (33%), nausea and vomiting
(18%), and muscular weakness (14%). Acute side effects were
less common with preoperative than postoperative chemora-
diotherapy. In the NSABP R03 study,74 which was recently
updated after the enrolment of 267 patients, more patients
tended to have grade 4–5 toxicity in the preoperative arm
compared with the postoperative arm (34% vs 23%; p = 0.07).
The largest difference was in grade 4 diarrhoea (24% vs 12%),
which was most pronounced during the period of radiation.
This study used a combination of bolus 5FU and FA in both
arms. Leucopenia, stomatitis and vomiting were the next most
common toxicities, with fewer than 10% of patients in either
arm suffering from grade 3 or greater toxicity during the entire
course of treatment.
Investigators from the much larger German trial, where
completion of accrual occurred in November 2002, recently
provided an updated progress report.75 Significantly, the find-
ings were very different to the NSABP R03 study and demon-
strated reduced acute toxicity in the preoperative chemoradio-
therapy setting. The principal toxicity was diarrhoea, with
World Health Organization grade 3–4 diarrhoea in 9% of the
preoperative arm vs 13% of the postoperative arm. Other acute
toxicities, such as grade 3 nausea and vomiting, grade 3
Table 5. Randomized controlled trials of adjuvant preoperative and postoperative chemotherapy and radiotherapy for rectal cancer
NSABP R0312 German (CAO/ARO/AIO-94)11
Postoperative RT Preoperative RT Postoperative RT Preoperative RT
 (50.4 Gy) + 5FU/LV (50.4 Gy) + 5FU/LV (50.4 Gy) + 5FU (50.4 Gy) + 5FU
n 57 59 310 318
Mortality (%) 2 4 1.2 1.6
Complications (%)
   Severe diarrhoea 23 39 12 9
   Nausea/vomiting 10 10 3 3
   Small bowel obstruction 6 3 3 1
   Fistula formation NS NS 1 3
   Anastomotic leak 4 9 12 13
   Delayed wound healing 2 3 6 5
   Postoperative bleeding NS NS 4 3
NSABP = National Surgical Adjuvant Breast and Bowel Project; RT = radiotherapy; 5FU = 5-fluorouracil; LV = leucovorin; NS = not stated.
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Table 6. Comparison of mortality and morbidity with adjuvant therapy for rectal cancer
Preoperative short-course Preoperative Postoperative
radiotherapy chemoradiotherapy chemoradiotherapy
Mortality (%) 2–4 1.6–4 0–4
Morbidity (%)
   Diarrhoea 2 9–34 7–35
   Nausea NS 3–10 3–33
   SBO/ileus 5–13 33–5
   Anastomotic leak 5–15 13 12
   Wound infection 4–5 4 6
   Perineal wound infection 20–26 NS NS
   Cardiovascular events 5 2– 53– 33
NS = not stated; SBO = small bowel obstruction.
erythema and grade 3 leucopenia, occurred in fewer patients
who received preoperative chemoradiotherapy. An early re-
port from the first 316 patients in the Polish trial,71 which is
comparing preoperative short-course radiotherapy and long-
course chemoradiotherapy, found a reduced overall acute
toxicity in patients who received radiotherapy alone (2% vs
17%).
In both NSABP R0374 and the German study,75 the inci-
dence of postoperative complications, including postopera-
tive bleeding, delayed wound healing, anastomotic leaks, SBO
and fistula formation, was not increased after preoperative
chemoradiotherapy.
Late adverse effects
Delayed adverse effects from combined-modality therapy have
not been well documented as only a few RCTs have recently
been completed. The late toxicity data are expected to become
available in the next 3 years.
Preoperative short-course radiotherapy
alone vs pre- and postoperative chemo-
radiotherapy
Our current practice is divided between these three options.
While postoperative chemoradiotherapy for high-risk (T3–4
or N1) rectal cancer is the standard adjuvant therapy, there are
several potential advantages with preoperative adjuvant thera-
py (radiotherapy alone or chemoradiotherapy). The rationale
for this is improved patient compliance and, possibly, re-
duced toxicities. A comparison of the toxicities in contempo-
rary studies using modern radiotherapeutic techniques is
shown in Table 6.1,2,5–13,38,58,59,61 The main difference between
postoperative and preoperative adjuvant therapy is the lower
incidence of acute gastrointestinal toxicity with preoperative
adjuvant therapy. Preoperative short-course radiotherapy
also causes less gastrointestinal toxicity than preoperative
chemoradiotherapy. This is obviously not unexpected as the
total dose of 25 Gy in five fractions is only biologically equiva-
lent with late-reacting tissues. A large dose fraction produces
relatively more damage to late-reacting than early-reacting
tissues because of the differences in dose response kinetics. In
order to avert potential toxicity in late-reacting tissues, the
final dose of 25 Gy in five fractions was calculated to be
biologically equivalent to 45 Gy delivered with conventional
fractionation. With preoperative short-course radiotherapy,
acutely reacting tissues such as skin and mucosal linings, and
potentially the cancer itself, will be exposed to a total dose that
is biologically lower than that delivered with preoperative
long-course radiotherapy.75 Concomitant administration of
chemotherapy might potentiate the toxicity of the radio-
therapy. There are no mature data from any trials comparing
preoperative short-course radiotherapy and postoperative
chemoradiotherapy, but a UKMRC trial comparing these two
approaches is currently accruing patients.
However, preoperative short-course radiotherapy causes
an increased incidence of perineal wound infection and break-
down compared with preoperative and postoperative che-
moradiotherapy.1,11,12,73,74 In addition, preoperative short-
course radiotherapy does not cause down-staging of can-
cer and, hence, is unlikely to improve sphincter preservation.
There is also an excess of cardiovascular events with pre-
operative short-course radiotherapy, most probably due to
the larger fraction size delivered compared with long-course
therapy.
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Summary
The standard of care in rectal cancer has changed over the last
few decades and will continue to evolve. Adjuvant therapy has
improved the oncological outcome in high-risk (T3–4 or N1)
rectal cancer. This benefit seems to be decreased with optimal
surgery.1,51 Any potential benefit of chemotherapy or radio-
therapy ought to be balanced against the proven toxicities of
adjuvant therapy. Documentation of therapeutic toxicity must
be more stringent and should include tools to assess quality of
life, as used in an Australian study.76 Much effort has been
expended to improve the planning and delivery of radio-
therapy and chemotherapy to minimize morbidity. However,
the future must involve a better selection of patients with
high-risk rectal cancer who are more likely to benefit from
adjuvant therapy, thus sparing others from unnecessary
morbidity associated with adjuvant therapy.
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